Undisclosed Neuromodulation Program
Treatment-Resistant Depression (TRD) and Acute Suicidality
Pre-clinicalActive
Key Facts
Indication
Treatment-Resistant Depression (TRD) and Acute Suicidality
Phase
Pre-clinical
Status
Active
Company
About NeuroQore
NeuroQore is an early-stage biotech startup founded in 2021, targeting a critical unmet need in mental health: rapid and effective treatment for patients with treatment-resistant depression (TRD) and acute suicidality. The company is developing novel neuromodulation therapies intended to overcome the limitations of current standards like electroconvulsive therapy (ECT), which has a delayed onset and significant side effects. Operating from the biotech hub of Cambridge, MA, NeuroQore is positioned to innovate in a high-burden therapeutic area with substantial market potential, though it remains in a pre-clinical, pre-revenue stage of development.
View full company profile